Beckman Coulter Acquires Chinese Flow Cytometer Maker
Xitogen has 48 associates, according to Beckman. Asked about the expected synergies, Beckman told IBO, “The Xitogen research cytometers are complementary to the BEC LS clinical cytometry portfolio and will fill out the company offerings for researchers using cytometry. In addition, the intended acquisition will provide an R&D and manufacturing footprint in China, an important addition to the R&D and manufacturing centers in North America (Miami; Fort Collins, Colorado; Indianapolis), Europe (Marseille), and India (Bangalore).”
Indianapolis, IN 4/22/14—Beckman Coulter Life Sciences has agreed to acquire Xitogen Technologies, a China-based flow cytometer company, together with Cytojene, for an undisclosed amount. Xitogen offers the XTG-1600 compact flow cytometer designed for basic research applications for the detection of objects in the 100 nm range. Beckman stated that Xitogen’s facilities in Suzhou and Dalian will function as R&D manufacturing centers for Beckman Coulter Life Sciences. “Having an operational base in the growing Asian market will enable us to provide timely service to customers in that region,” stated Mario Koksch, vice president and general manager of the Beckman Coulter Life Sciences’ Cytometry Business Unit. “Adding this technology and intellectual property to our existing portfolio means we can extend our reach from clinical diagnostics through clinical research and further into basic research.” The transaction is expected to close in the second quarter.
